Peptides
CagriSema Arrives: Phase 3 Data Suggest the Amylin–GLP-1 Combo Edges Past Semaglutide
Two simultaneous Lancet trials test Novo Nordisk's next-generation incretin against the current heavyweight. Here's what a busy 40-year-old should actually take from the readout.